Active Filter(s):
Details:
The collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET. The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 26, 2023